Barclays PLC Buys 373,032 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Barclays PLC increased its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 68.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 916,368 shares of the biotechnology company's stock after acquiring an additional 373,032 shares during the quarter. Barclays PLC owned about 0.13% of OPKO Health worth $1,347,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of OPK. Wells Fargo & Company MN lifted its holdings in shares of OPKO Health by 14.9% during the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock valued at $337,000 after purchasing an additional 29,738 shares in the last quarter. Cibc World Markets Corp acquired a new stake in OPKO Health in the fourth quarter valued at $45,000. Ieq Capital LLC bought a new position in OPKO Health during the fourth quarter worth about $52,000. World Investment Advisors LLC acquired a new position in shares of OPKO Health during the 3rd quarter worth approximately $61,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of OPKO Health during the 4th quarter worth about $91,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Trading Down 5.9 %

Shares of OPKO Health stock traded down $0.08 on Tuesday, hitting $1.28. 9,836,690 shares of the company's stock traded hands, compared to its average volume of 3,892,806. The company has a market capitalization of $859.58 million, a price-to-earnings ratio of -6.74 and a beta of 1.42. OPKO Health, Inc. has a one year low of $1.15 and a one year high of $2.04. The company has a fifty day moving average of $1.60 and a two-hundred day moving average of $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business's quarterly revenue was down 13.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) EPS. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was bought at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the completion of the transaction, the chief executive officer now owns 214,001,448 shares of the company's stock, valued at $291,041,969.28. The trade was a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have bought 767,434 shares of company stock valued at $1,238,312 over the last ninety days. Corporate insiders own 49.69% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. StockNews.com cut OPKO Health from a "hold" rating to a "sell" rating in a report on Monday. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Monday, April 7th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They issued a "neutral" rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.